BE661313A - - Google Patents
Info
- Publication number
- BE661313A BE661313A BE661313DA BE661313A BE 661313 A BE661313 A BE 661313A BE 661313D A BE661313D A BE 661313DA BE 661313 A BE661313 A BE 661313A
- Authority
- BE
- Belgium
- Prior art keywords
- octane
- class
- grams
- desc
- page number
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 11
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- -1 2-trifluoromethylphenothiazinyl Chemical group 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 7
- 229950000688 phenothiazine Drugs 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000003204 tranquilizing agent Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical compound C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 description 1
- 241001133900 Tarne Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- CBHCDHNUZWWAPP-UHFFFAOYSA-N pecazine Chemical compound C1N(C)CCCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 CBHCDHNUZWWAPP-UHFFFAOYSA-N 0.000 description 1
- 229950007538 pecazine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE661313T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE661313A true BE661313A (enrdf_load_stackoverflow) |
Family
ID=3877136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE661313D BE661313A (enrdf_load_stackoverflow) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE661313A (enrdf_load_stackoverflow) |
-
0
- BE BE661313D patent/BE661313A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH644348A5 (fr) | Amino-ethers oxydes, leur procede de preparation et medicament les contenant. | |
| EP0073161B1 (fr) | Nouveaux dérivés de la pyrazine actifs sur le système nerveux central | |
| EP0072299A2 (fr) | Nouveaux dérivés de la méthyl-4 phényl-6 pyridazines actifs sur le système nerveux central | |
| LU81676A1 (fr) | Nouveaux derives d'aurones,leur procede de preparation et leur utilisation comme produits pharmaceutiques | |
| BE661313A (enrdf_load_stackoverflow) | ||
| BE884387A (fr) | Composition a base d'acides aryloxyalkylaminobenzoiques, leurs sels et leurs esters | |
| EP0079810B1 (fr) | Nouveaux dérivés de la phényl-4 quinazoline actifs sur le système nerveux central | |
| EP0077427A1 (fr) | Dérivés de pipéridine, leur procédé de préparation et leur application en thérapeutique | |
| EP0089894A1 (fr) | (Benzimidazolyl-1)-1,N-((hydroxy-4 méthoxy-3 phényl)-2 hydroxy-2 éthyl) amino-3 butane et ses sels et hydrates à activité bêta-adrénergique, leurs applications thérapeutiques, et procédé pour les préparer | |
| EP0320362A1 (fr) | Utilisation de dérivés de hydroxy-3 (méthoxy-4 phényl)-2 (méthylamino-2 éthyl)-5 dihydro-2,3 5H-benzothiazépine-1,5 one-4 pour la préparation de médicaments inhibiteurs du facteur d'activation des plaquettes | |
| EP0303545B1 (fr) | Procédé pour la préparation de phényléthanolaminotétralines | |
| BE854655A (fr) | 9-hydroxyhexahydrobenzo (c) quinoleines et intermediaires de synthese | |
| EP0183577B1 (fr) | Dérivés du thiadiazole actifs sur le système nerveux central, procédé d'obtension et compositions pharmaceutiques les contenant | |
| CA2366820C (fr) | Nouveaux derives de [(2-substitue-5 -[3-thienyl]) -benzyl]-[2- ([2-isopropoxy-5-fluoro] -phenoxy) -ethyl] -amine, leur procede de preparation et leur utilisation a titre de medicaments | |
| EP0064006A1 (fr) | Chlorures de dialcoxy (2,4) benzènesulfonyle substitués | |
| FR2614299A1 (fr) | Composes diamino benzeniques iodes, leur procede de preparation et produits de contraste les contenant. | |
| EP0081425B1 (fr) | Compositions pharmaceutiques présentant des propriétés normolipémiantes et contenant des composés ayant une structure du type benzènesulfonamides n-substitués | |
| CA1068270A (fr) | Diamino-2,4-bromo-5 chloro-6 pyrimidines utilisables comme medicaments et procede pour leur preparation | |
| CH618977A5 (enrdf_load_stackoverflow) | ||
| BE503348A (enrdf_load_stackoverflow) | ||
| BE884657R (fr) | Nouveaux derives de 1-(3-(3,4,5-trimethoxyphenoxy)-2-hydroxy-propyl)-4-aryl-piperazines et procede pour leur preparation ainsi que leur utilisation a titre de medicament | |
| BE565941A (enrdf_load_stackoverflow) | ||
| BE568268A (enrdf_load_stackoverflow) | ||
| BE734126A (enrdf_load_stackoverflow) | ||
| BE493470A (enrdf_load_stackoverflow) |